Laboratory of Veterinary Clinical Oncology, Department of Veterinary Medicine, Gifu University, Gifu, Japan.
Vet Comp Oncol. 2011 Sep;9(3):219-24. doi: 10.1111/j.1476-5829.2010.00253.x. Epub 2011 Jan 17.
KIT, a transmembrane receptor tyrosine kinase, is one of the specific targets for anti-cancer therapy. In humans, its expression and mutations have been identified in malignant melanomas and therapies using molecular-targeted agents have been promising in these tumours. As human malignant melanoma, canine malignant melanoma is a fatal disease with metastases and the poor response has been observed with all standard protocols. In our study, KIT expression and exon 11 mutations in dogs with histologically confirmed malignant oral melanomas were evaluated. Although 20 of 39 cases were positive for KIT protein, there was no significant difference between KIT expression and overall survival. Moreover, polymerase chain reaction amplification and sequencing of KIT exon 11 in 17 samples did not detect any mutations and proved disappointing. For several reasons, however, KIT expression and mutations of various exons including exon 11 should be investigated in more cases.
KIT 是一种跨膜受体酪氨酸激酶，是癌症治疗的特定靶点之一。在人类中，其表达和突变已在恶性黑色素瘤中被鉴定出来，并且使用分子靶向药物的治疗在这些肿瘤中很有前景。与人类恶性黑色素瘤一样，犬恶性黑色素瘤是一种致命的疾病，会发生转移，并且所有标准方案的反应都很差。在我们的研究中，评估了经组织学证实的恶性口腔黑色素瘤犬的 KIT 表达和外显子 11 突变。尽管 39 例中有 20 例 KIT 蛋白阳性，但 KIT 表达与总生存率之间无显著差异。此外，在 17 个样本中，对 KIT 外显子 11 的聚合酶链反应扩增和测序未检测到任何突变，结果令人失望。然而，出于多种原因，包括外显子 11 在内的各种外显子的 KIT 表达和突变应该在更多的病例中进行研究。
